Hayakawa, F
Sakura, T
Yujiri, T
Kondo, E
Fujimaki, K
Sasaki, O
Miyatake, J
Handa, H
Ueda, Y
Aoyama, Y
Takada, S
Tanaka, Y
Usui, N
Miyawaki, S
Suenobu, S
Horibe, K
Kiyoi, H
Ohnishi, K
Miyazaki, Y
Ohtake, S
Kobayashi, Y
Matsuo, K
Naoe, T
,
Article History
Received: 30 August 2014
Accepted: 8 September 2014
First Online: 17 October 2014
Competing interests
: Consultancy: NU (Pfizer) and TN (Pfizer). Honoraria: OS (Kyowahakko-Kirin); HH (Kyowahakko-Kirin, Nippon Shinyaku); YA (Kyowahakko-Kirin, Shionogi); NU (Kyowahakko-Kirin, Nippon Shinyaku, Shionogi, Pfizer); YM (Kyowahakko-Kirin, Nippon Shinyaku, Pfizer); YK (Nippon Shinyaku); TN (Kyowahakko-Kirin, Nippon Shinyaku, Shionogi). Research funding: JM (Kyowahakko-Kirin, Shionogi, Pfizer); NU (Kyowahakko-Kirin, Nippon Shinyaku, Shionogi, Pfizer, Meiji Seika Pharma); HK (Bristol-Myers Squibb, Chugai Pharmaceutical, Kyowahakko-Kirin, Dainippon Sumitomo Pharma, Zenyaku Kogyo and FUJIFILM Corporation); YM (Kyowahakko-Kirin, Pfizer); YK (Pfizer); TN (Kyowahakko-Kirin).